Vexev's VxWave System Achieves Major Success in Clinical Study for Dialysis Clinics

Vexev's VxWave System Achieves Clinical Milestones in Dialysis

In a groundbreaking development within the field of vascular imaging, Vexev, an innovative medical device company based in Australia, has successfully demonstrated the efficacy of its VxWave Ultrasound Imaging System. This pioneering robotic platform has shown promising results in a landmark clinical trial known as the CANSCAN Trial (NCT06691672). Conducted in collaboration with U.S. Renal Care at dialysis clinics across the United States, the study aimed to evaluate the feasibility and effectiveness of automated vascular mapping in patients requiring hemodialysis.

The CANSCAN Trial’s results were presented by Dr. Varshi Broumand, the principal investigator, at the American Society of Nephrology's annual meeting, Kidney Week 2025, in Houston, Texas. The study involved 115 patients suffering from chronic kidney disease (CKD) and demonstrated significant success rates, including a remarkable 94% scan completion rate and an exceptional 100% data adequacy rate. These findings suggest that the VxWave System could revolutionize the way vascular access is planned and implemented for dialysis treatments.

Hemodialysis patients rely heavily on effective vascular access, primarily through arteriovenous fistulas (AVFs). However, statistics reveal that nearly 75% of AVFs fail to mature adequately or are abandoned prior to use. Traditional methods of vascular mapping have faced challenges such as inefficient scheduling outside of dialysis appointments, inconsistent quality, and high costs. Dr. Broumand emphasized the importance of these barriers: “The results from the CANSCAN Trial signify a paradigm shift, allowing high-quality vascular imaging to be performed on-demand within the dialysis clinic, ultimately improving patient outcomes.”

The VxWave Ultrasound Imaging System utilizes advanced robotics, machine learning, and sophisticated ultrasound signal processing to create detailed 3D vascular models. This innovation allows for a comprehensive and standardized assessment of vascular anatomy directly at the point of care. Dr. Shannon Thomas, Chief Medical Officer at Vexev, stated, “The success we've seen in the CANSCAN Trial provides a robust foundation toward achieving high-quality, standardized, point-of-care vascular assessments globally.”

Additionally, the CANSCAN Trial provided critical insights into the vascular anatomy of CKD stage 4 and 5 patients, revealing discrepancies among subgroups that may face challenges in accessing suitable vascular sites. Notably, patients with diabetes exhibited increased calcification in their upper limb arteries, contributing to reduced diameters in their forearm veins. The study also highlighted gender differences, with female patients generally having fewer and smaller veins compared to their male counterparts. Such findings underscore the potential for the VxWave System to identify at-risk groups and improve outcomes for patients facing vascular access difficulties.

“This innovative solution from Vexev represents one of the most promising advancements we've encountered in recent years,” commented Dr. Geoff Block, Associate Chief Medical Officer and Senior Vice President of Clinical Research at U.S. Renal Care. “The results hint at real potential to enhance the quality of care provided to patients as we work towards broader implementation of an automated, point-of-care imaging approach across our network.”

Vexev was founded in 2018 by Dr. John Carroll and Dr. Eamonn Colley, both experts in vascular fluid dynamics and computational imaging. The company's mission is to transform blood-flow research into technologies that yield better health outcomes for patients in need of vascular and renal care. Their ongoing commitment in this innovatory domain is emblematic of future breakthroughs aimed at improving the quality of life for individuals undergoing dialysis treatment.

For more information about Vexev and its advancements in vascular imaging technology, visit Vexev.com. Similarly, U.S. Renal Care has established itself as a leading provider of in-center and home dialysis, offering care to over 36,000 patients nationwide. Discover more about their impact on patient care at USRenalCare.com.